{"nctId":"NCT00871494","briefTitle":"Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan","startDateStruct":{"date":"2009-05"},"conditions":["Pelvic Inflammatory Disease"],"count":76,"armGroups":[{"label":"Azithromycin switch therapy (switch from intravenous to oral).","type":"EXPERIMENTAL","interventionNames":["Drug: Azithromycin"]}],"interventions":[{"name":"Azithromycin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nBoth of following symptoms should be observed.\n\n* Lower abdominal pain and/or lower abdominal tenderness.\n* Hypochondrial pain and/or hypochondrial tenderness (tenderness of uterus or adnexa of uterus).\n\nExclusion Criteria:\n\nKnown or suspected hypersensitivity or intolerance to azithromycin, other macrolides, or ketolides.\n\nHepatic dysfunction (AST, ALT, total bilirubin \\> 3 times institutional normal).","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"16 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Response Rate (Clinical Response, Data Review Committee Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃ or Higher Was Option)","description":"Response rate was calculated from the following formula, \"the number of participants assessed as effective\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100.\n\nThe inclusion criterion regarding fever was amended from the required criteria to the additional criteria in consultation with the regulatory authority. The subset of participants who were enrolled after the protocol amendment was the primary analysis sets for efficacy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate (Clinical Response, Investigator Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃ or Higher Was Option)","description":"Response rate was calculated from the following formula, \"the number of participants assessed as effective\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100.\n\nThe inclusion criterion regarding fever was amended from the required criteria to the additional criteria in consultation with the regulatory authority. The subset of participants who were enrolled after the protocol amendment was the primary analysis sets for efficacy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Eradication Rate (Bacteriological Response, Data Review Committee Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃ or Higher Was Option)","description":"Eradication Rate was calculated from the following formula, \"the number of participants assessed as eradication, presumed eradication and microbial substitution\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100.\n\nThe inclusion criterion regarding fever was amended from the required criteria to the additional criteria in consultation with the regulatory authority. The subset of participants who were enrolled after the protocol amendment was the primary analysis sets for efficacy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Eradication Rate (Bacteriological Response, Investigator Assessment) in Participants Who Enrolled After Protocol Amendment (the Inclusion Criterion Regarding Fever of 37℃ or Higher Was Option)","description":"Eradication Rate was calculated from the following formula, \"the number of participants assessed as eradication , presumed eradication and microbial substitution\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100.\n\nThe inclusion criterion regarding fever was amended from the required criteria to the additional criteria in consultation with the regulatory authority. The subset of participants who were enrolled after the protocol amendment was the primary analysis sets for efficacy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":76},"commonTop":["Diarrhoea","Injection site pain","Nausea","Nasopharyngitis","Abdominal tenderness"]}}}